

Supplemental Table S1

Cell-Free DNA Sequencing reveals Gene Variants in DNA Damage Repair Genes associated with Prognosis in Prostate Cancer Patients

Verena Lieb^{1,2}, Amer Abdulrahman^{1,2}, Katrin Weigelt^{1,2}, Siegfried Hauch³, Michael Gombert³, Juan Guzman^{1,2}, Laura Bellut^{1,2}, Peter Goebell^{1,2}, Robert Stöhr^{2,4}, Arndt Hartmann^{2,4}, Bernd Wullich^{1,2}, Helge Taubert^{1,2,5,*}, Sven Wach^{1,2,5}

Suppl. Table S1. Clinicopathological data, treatment and study data

Parameter	n
Patients	34
Samples	39
Age, median (range) in years	67 (48-89)
Metastasis	
cM0	3
cM1	31
cfDNA, mean (range) in ng/ml	17.93 (2.37-206.25)
CTC-positive patients (samples)	9 (11)
AR-V7-CTC-positive patients (samples)	3 (4)
Survival time, median (range) in months	48 (6-182)
Overall survival	
Alive	24
Dead	10
Disease-specific survival	
Yes	25
No	9
Time from blood sampling to last contact, median (range)	10 (0-61)
Time from metastasis to last follow up, median (range)	31 (11-133)
Time to treatment change	9 (1-40)
Treatment change	
Yes	24
No	8
Not known	2
Pretreatment	
None	6
Depriv	10
AE	8
Tax	3
Multiple	7
Treatment	
AE	10
Tax	18
Chemotherapy/hormone	6
Pretreatment + treatment	

None + chemotherapy/hormone	6
Depriv + AE	5
Tax + AE	4
Mult + AE	2
Depriv + Tax	4
AE + Tax	8
Mult + Tax	5

Abbreviations: None, no pretreatment; Depriv, hormone deprivation; AE, antiandrogens abiraterone/enzalutamide; Tax, taxanes; Mult, multiple (both AE and Tax). Chemotherapy/hormone following none, AE following Depriv, AE following Tax, AE following Mult, Tax following Depriv, Tax following AE, Tax following Mult.